Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers-Reference-Cited by-同舟云学术

Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers

Published:2023-01-02 Issue:1 Volume:19 Page:43-51
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Mu Guangyan¹,Xie Qiufen¹,Liu Zhiyan¹,Zhang Hanxu¹²,Meng Xianmin³,Song Jinfang⁴,Zhou Shuang¹,Wang Zhe¹,Wang Zining¹,Zhao Xia¹,Jiang Jie⁵,Liao Maoxing³,Bao Jiachun⁴,Zhang Fan¹,Xiang Qian¹,Cui Yimin¹²⁶

Affiliation:

1. Department of Pharmacy, Peking University First Hospital, Beijing, China

2. School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China

3. Department of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China

4. Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, China

5. Department of Cardiology, Peking University First Hospital, Beijing, China

6. Institute of Clinical Pharmacology, Peking University, Beijing, China

Funder

National Key R&D Program of China

National Science and Technology Major Projects for ‘Major New Drugs Innovation and Development’

National Natural Science Foundation of China

Beijing Municipal Commission of Science and Technology of China Pharmaceutical Innovation Cultivation and Industry Support Platform Capacity Construction Project

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2023.2184344

Reference46 articles.

1. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

2. Apixaban versus Warfarin in Patients with Atrial Fibrillation

3. Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban

4. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes

5. Real-world assessment of off-label direct oral anticoagulant dosing for venous thromboembolism

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Pharmacogenetics: From Discovery of Genetic Association to Clinical Adoption of Derived Test;Pharmacological Reviews;2024-08-09